Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where
active study drug (QPI-1007) will be given to all patients who participate.
This study will determine whether QPI-1007 is safe when it is injected into the eye. The
study will also reveal if there are any side effects of the drug and how long it takes for
the body to clear the drug.